Wunderlich Securities Maintains Buy Rating on Abiomed

According to Wunderlich Securities, Abiomed ABMD Buy rating is maintained. Wunderlich Securities said that it hosted a call with ABMD management on Thursday to review several recent, positive developments with the company, and to address recent misinformation that has caused weakness in the stock. “We believe investors should take advantage of the pullback to buy ABMD shares, and continue to view Abiomed one of the best stories in the Medtech sector.” Abiomed closed yesterday at $18.52.